Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The company's lead clinical program is indiplon, a candidate for treating insomnia. Following the termination of a collaboration with Pfizer in December 2006, Neurocrine reacquired all worldwide rights to indiplon and is responsible for its development, registration, and commercialization.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Total Revenues | $0.1 million | $19.5 million |
| Net Loss | $(25.7) million | $(25.9) million |
| Loss Per Share (Basic & Diluted) | $(0.68) | $(0.69) |
| Operating Expenses | $27.4 million | $47.1 million |
| Cash and Cash Equivalents | $78.5 million | $101.5 million (end of period) |
| Short-term Investments | $88.3 million | $101.6 million (end of period) |
| Total Current Assets | $170.3 million | $193.7 million |
| Total Liabilities | $72.0 million | $75.0 million |
| Long-term Debt | $48.5 million | $49.2 million |
| Net Cash Used in Operating Activities | $(14.9) million | $(20.4) million |
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped from $19.5 million in Q1 2006 to $0.1 million in Q1 2007. The 2006 figure included $18.5 million from the terminated Pfizer collaboration (sponsored development, license fees, and sales force allowance). Q1 2007 revenue consisted primarily of a $18,000 grant from the Michael J. Fox Foundation.
- Expense Reduction: Total operating expenses decreased by approximately $19.7 million year-over-year.
- R&D Expenses: Decreased from $27.7 million to $19.1 million due to staff reductions (saving $4.2 million in personnel costs) and lower external development costs, partially offset by increased spending on indiplon and GnRH programs.
- SG&A Expenses: Decreased from $19.3 million to $8.3 million, primarily due to cost savings from staff reductions implemented in 2006.
- Share-Based Compensation: Non-cash share-based compensation expense decreased significantly from $6.8 million in Q1 2006 to $2.4 million in Q1 2007.
- Liquidity: Total cash, cash equivalents, and short-term investments decreased from $182.6 million at year-end 2006 to $166.8 million at March 31, 2007, driven by the net loss for the quarter.
Outlook, Risks, and Management Commentary
- Indiplon Regulatory Status:
- Capsules: FDA issued an "Approvable" letter for 5 mg and 10 mg capsules. Neurocrine has completed requested reanalyses and a supplemental pharmacokinetic profile. The NDA resubmission is targeted for the end of Q2 2007.
- Tablets: FDA issued a "Not Approvable" letter for 15 mg tablets, requesting additional long-term safety/efficacy data and a separate dose for the elderly. The company is formulating a strategy to pursue a sleep maintenance claim.
- Commercialization Strategy: Following the Pfizer termination, Neurocrine must either find a new partner or build its own sales and marketing infrastructure to commercialize indiplon. The company terminated its sales force in July 2006.
- Liquidity and Capital Resources: Management believes existing capital resources ($166.8 million in cash/investments) are sufficient to fund operations for at least the next 12 months. However, additional funding may be required for future R&D, clinical trials, and commercialization efforts.
- Impairment Risk: The company holds a $94.0 million prepaid royalty asset related to indiplon. While no impairment was recognized as of March 31, 2007, management notes that further FDA delays, failure to secure a partner, or commercialization failures could trigger a material impairment charge.
- Profitability: The company expects to incur operating losses for the foreseeable future due to the loss of Pfizer revenue and the costs associated with independent development and commercialization of indiplon.
Investor Verification Checklist
- Indiplon NDA Resubmission: Verify the timing and content of the NDA resubmission for indiplon capsules targeted for Q2 2007.
- Partnership Status: Monitor announcements regarding the search for a new commercialization partner for indiplon or plans to build an internal sales force.
- Prepaid Royalty Asset: Watch for any future impairment charges related to the $94.0 million prepaid royalty asset if FDA approval is delayed or commercialization prospects diminish.
- Cash Burn Rate: Track quarterly cash usage to ensure the $166.8 million liquidity position remains sufficient to fund operations through the next 12 months without dilutive equity raises.
- Regulatory Updates: Monitor FDA communications regarding the "Not Approvable" tablet formulation and the requirements for the sleep maintenance claim.